FDA Grants Accelerated Approval to Iberdomide Combination for Multiple Myeloma
A new FDA accelerated approval introduces an iberdomide-based combination for certain adults with previously treated multiple myeloma.
New FDA Approval for Multiple Myeloma
On 13 August 2026, the U.S. Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for certain adults with multiple myeloma.
The combination is intended for adults who have received at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent.
What Does the Combination Include?
A New Treatment Option in Multiple Myeloma
Advances in targeted and immune-based therapies continue to expand treatment options for patients with previously treated multiple myeloma.
What Is Iberdomide?
Iberdomide is an orally administered immunomodulatory medicine developed for the treatment of multiple myeloma and other hematologic malignancies.
Its inclusion in an FDA-approved combination is important for pharmacy, oncology and pharmaceutical research because it provides another therapeutic option for patients whose disease has required previous treatment.
👥 Who is the FDA-approved combination intended for?
Adults with multiple myeloma who have received at least one prior line of therapy that included both a proteasome inhibitor and an immunomodulatory agent.
FDA-Listed Iberdomide Dosage
The recommended dose of iberdomide is 1 mg orally once daily, with or without food, on Days 1 through 21 of a 28-day treatment cycle when used as part of the approved combination.
Treatment schedules for daratumumab/hyaluronidase-fihj and dexamethasone should be followed according to their approved prescribing information.
Why This Approval Matters
- Provides an additional treatment option for previously treated multiple myeloma.
- Combines an oral immunomodulatory medicine with anti-CD38-based therapy and dexamethasone.
- Represents an important development for oncology pharmacy and hematologic cancer treatment.
- Highlights continued pharmaceutical research into therapies for patients requiring additional lines of treatment.
⚡ What Does Accelerated Approval Mean?
This medicine received approval through the FDA Accelerated Approval pathway. Accelerated approval allows certain medicines addressing serious conditions to reach patients based on evidence reasonably likely to predict clinical benefit.
Continued approval may depend on additional confirmatory evidence demonstrating clinical benefit.
Official FDA Source
Readers can review the full regulatory announcement, treatment schedule and clinical information directly from the U.S. Food and Drug Administration.
Read Official FDA Announcement →Medical Disclaimer: This article is intended for educational and informational purposes only. It should not be considered medical advice, diagnosis or a recommendation to use any medicine. Cancer treatment must be determined by qualified healthcare professionals according to the individual patient’s condition.
